Study Shows Detection of Hydrocodone and Morphine as Metabolites of Codeine
Millennium Health announced the publication of a new study that identifies hydrocodone and morphine as metabolites in oral fluid using Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) in patients prescribed codeine. The study was published in the February 2017 issue of Therapeutic Drug Monitoring.
“Understanding that hydrocodone and morphine may be found as metabolites for patients prescribed codeine helps improve interpretation of oral fluid testing used to monitor patients prescribed opioids,” said Maria Guevara, Pharm.D., director of clinical affairs, education and training, Millennium Health. “In a clinical context, it could mean that a clinician does not falsely accuse a patient of having taken a concomitant medication.”
In the study, oral fluid samples were collected and submitted to Millennium for routine drug testing using LC-MS/MS. Consistent with previously published literature, codeine was the primary analyte detected in oral fluid after the use of codeine. In codeine-positive samples, hydrocodone, morphine, and norhydrocodone were detected. In contrast to urine, where hydrocodone is typically detected as a minor metabolite of codeine, hydrocodone was the most commonly detected metabolite in oral fluid samples testing positive for codeine with reported prescriptions for codeine.
The results of the study suggest that care should be taken when interpreting hydrocodone positives in oral fluid test results, and that the use of codeine should be considered as one possible explanation for hydrocodone and morphine positives.
West, R. E., Guevara, M. G., Mikel, C., & Gamez, R. (2017). Detection of Hydrocodone and morphine as metabolites in oral fluid by LC-MS/MS in patients prescribed Codeine. Therapeutic Drug Monitoring, 39(1), 88–90. doi:10.1097/ftd.0000000000000365
This article has been republished from materials provided by Millennium Health. Note: material may have been edited for length and content. For further information, please contact the cited source.
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Comments | 0 ADD COMMENT
International Conference on Nanomedicine and Nanotechnology
Aug 20 - Aug 21, 2018